HC Wainwright Issues Negative Outlook for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Eton Pharmaceuticals in a report issued on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.04 per share for the quarter, down from their prior estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share.

A number of other equities analysts have also recently issued reports on ETON. B. Riley began coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $21.00 price objective for the company. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Stock Up 2.6 %

ETON opened at $16.67 on Friday. The business has a fifty day moving average of $12.84 and a 200 day moving average of $8.25. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $17.00. The stock has a market cap of $434.27 million, a P/E ratio of -75.77 and a beta of 1.38.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Baader Bank Aktiengesellschaft purchased a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth $373,000. Westside Investment Management Inc. lifted its holdings in shares of Eton Pharmaceuticals by 5.7% in the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after buying an additional 33,275 shares during the period. Geode Capital Management LLC raised its position in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after acquiring an additional 32,365 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth $90,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after acquiring an additional 7,029 shares in the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.